News headlines about Taro Pharmaceutical Industries (NYSE:TARO) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Taro Pharmaceutical Industries earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.713117532223 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Several equities analysts have recently weighed in on TARO shares. TheStreet lowered shares of Taro Pharmaceutical Industries from a “b-” rating to a “c+” rating in a report on Wednesday, August 9th. BidaskClub lowered shares of Taro Pharmaceutical Industries from a “hold” rating to a “sell” rating in a report on Friday, August 11th.
Shares of Taro Pharmaceutical Industries (NYSE:TARO) traded down $1.10 during midday trading on Thursday, hitting $104.50. 189,311 shares of the stock traded hands, compared to its average volume of 107,368. Taro Pharmaceutical Industries has a 52-week low of $94.00 and a 52-week high of $128.46. The firm has a market capitalization of $4,241.59, a price-to-earnings ratio of 13.03 and a beta of 0.62.
COPYRIGHT VIOLATION WARNING: This report was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.thelincolnianonline.com/2017/12/07/taro-pharmaceutical-industries-taro-given-coverage-optimism-score-of-0-18.html.
About Taro Pharmaceutical Industries
Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.
Receive News & Ratings for Taro Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.